STAT+: Cassidy pitches his alternative to extending extra ACA subsidies
Cassidy wants to replace enhanced ACA subsidies with payments to health savings accounts.
STAT+: Many poor countries where experimental drugs are tested fail to benefit after approval, analysis finds
A new analysis finds medicines often are not accessible countries where they were tested before approval by the FDA, raising concerns about ethical standards by industry.
STAT+: FDA clears spinal cord stimulator for home use
The FDA has cleared home use of a device that helps people with spinal cord injuries regain mobility and functioning.
NIH funding cuts have affected over 74,000 people enrolled in experiments, a new report says
Over 74,000 people enrolled in experiments have been affected by the NIH's funding cuts, according to a new report.
STAT+: Johnson & Johnson acquires Halda Therapeutics for $3 billion, a big win for a buzzy new technology
Johnson & Johnson said it will purchase Halda Therapeutics, marking the first major buyout for a cancer drugmaker built around so-called PROTACs, a buzzy new technology.
STAT+: European firms raise two big funds for early biotech
And more biotech news brought to you by The Readout
STAT+: Pharmalittle: We’re reading about Novo plans for Wegovy, a Purdue bankruptcy deal, and more
Novo Nordisk has begun selling Wegovy for $349 a month to cash payers, months ahead of the timeline set out with the Trump administration
A cervical cancer prevention milestone
And other health stories from Morning Rounds
STAT+: Nuvalent sees success for its second genetically targeted lung cancer drug
Nuvalent said its drug for ALK+ lung cancer shrank tumors in more than a quarter of patients whose disease had returned after trying other targeted medicines
Brain organoid pioneers fear inflated claims about biocomputing could backfire
Despite widespread skepticism, the National Science Foundation and DARPA have invested millions of dollars in organoid-based biocomputing